Whether these non-ASC expression domains will impact on the utility of any anti-ITM2C mAb therapy remains to be determined, but it is noteworthy that the two clinically approved mAb for MM, Daratumumab (CD38) and Elotuzumab (SLAMF7) target antigens expressed on ASC and multiple other cell types. Here, CD38 is linked to Miyoshi myopathy.